Latest news with #SanjeevJain
Time Business News
16 hours ago
- Business
- Time Business News
How parsvnath CEO Sanjeev Jain Is Leading the Future?
As everyone is aware, the real estate industry is expanding in this fast-paced world. One of India's top real estate firms is Parsvnath Developers, led by Parsvnath CEO Sanjeev Jain. They provide the highest caliber eco-friendly homes and offices. Parsvnath has established a solid name in this field with its thirty years of experience. All of this is due to our CEO, Sanjeev Jain, whose creative ideas have led to the construction of residences. Sanjeev Jain never loses sight of the client's needs. He regularly keeps an eye on homebuyers and the latest market trends. Under his direction, the business produces buildings with cutting-edge technology and environmentally friendly features. According to him, creating a home involves more than simply constructing a structure; it also entails using the highest quality, environmentally friendly materials. Parsvnath Developers constructs homes with sturdy structures and high-quality materials by employing clever building processes. They incorporate eco-friendly materials and other elements into their homes and workplaces. Techniques for conserving energy Automatic elements such as fans and lighting that can be controlled by a remote The Internet of Things, or IoT Homes in Parsvnath are constructed with contemporary styles and a range of lifestyles to accommodate various price ranges. They provide: They constructed residences with a variety of amenities and creative designs. Eco-friendly features were included in their dwellings. They have well-located projects. They provide the greatest and most comfortable layouts. Additionally, Parsvnath developers create smart offices with the best structures and opulent amenities. They employ designs that save energy. Their developments are close to workplaces and markets. Sustainability, which is what everyone demands these days, is the foundation of every initiative. Solar systems and rainwater collecting environmentally friendly construction materials Open spaces and gardens They offer top-notch projects and a wholesome setting. Parsvnath puts the client first at all times. They provide: Real Deal Timely Project Delivery Beneficial assistance Intelligent property administration Having completed numerous successful projects in the past, Parsvnath, under the leadership of CEO Sanjeev Jain, is now preparing for more. Parsvnath CEO Sanjeev Jain aims to expand into smaller cities and develop smart townships with top-notch amenities. New Collaborations & Creative Concepts In order to stand out in the market and become one of the most reputable developers in India, Parsvnath developers primarily concentrate on creative design using environmentally friendly materials, sustainability, and customer happiness. TIME BUSINESS NEWS
Fashion Value Chain
27-05-2025
- Business
- Fashion Value Chain
Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%
Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. The fourth quarter marked a significant rebound in performance, laying a strong foundation for continued growth and global expansion. In Q4 FY25, Akums reported revenue of Rs.1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin. Building on its Q4 momentum, Akums closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year. The company continued its focus on enhancing its product mix, building a differentiated, research-driven portfolio, and expanding its global presence. One of the key developments during the fiscal year was securing an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets – a milestone that significantly expands Akums' global CDMO footprint. The commercial supplies for this will begin in 2027. To support its expanding footprint, Akums invested Rs. 272 crore in capital expenditure during FY25. which now stands at 49.6 billion units annually. This infrastructure scale-up ensures readiness for large-scale domestic CDMO operations as well as global pharma opportunities. Akums also maintained a strong R&D focus, investing Rs. 130 crore which is over 3% of revenue. With 973 DCGI approvals now, the company's product portfolio has over 4,000 commercialized formulations. This is across multiple therapeutic areas across 60+ dosage forms. Segmental Performance Overview Akums' flagship business, CDMO, contributed ~78% to the group turnover with an adjusted EBITDA of 14.1% in FY 25. The company's domestic branded formulation business segment reported ~9% growth while international branded formulation business grew by ~14%. Trade generics and API segment continue to be in operational loss this fiscal, but the company is taking firm measures to cut the losses in the coming fiscal. Strategic Focus and Future Outlook Despite making meaningful progress across key business segments, Akums reported flat year-on-year revenue, largely due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India's pharmaceutical landscape and lay the foundation for global CDMO expansion. With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company's emphasis on quality-focused manufacturing, novel delivery formats, and patient-centric innovations ensures that its offerings are both globally relevant and therapeutically effective. Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, ' As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums' global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies.' Mr. Sandeep Jain, Managing Director, added, 'It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals-operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization.' Here is the Summary of Profit and Loss Statement for reference P/L (Rs Cr) Q4 FY 25 Q3 FY 25 Q4 FY 24 FY 25 FY 24 Revenue 1,056 1,010 944 4,118 4,178 Other Income 18 15 10 52 34 Total income 1,073 1,025 954 4,170 4,212 COGS 639 602 569 2,433 2,550 Employee Cost 184 176 164 716 647 Other Expenses 139 111 128 508 500 Adj EBITDA 111 136 98 513 515 Adj EBITDA Margin 10.4% 13.3% 10.3% 12.3% 12.2% Depreciation 40 45 34 153 126 Finance Cost 5 5 12 35 51 Exceptional Item -8 -5 0 -17 26 Adj PAT 44 66 46 234 220 Adj PAT Margin 4.1% 6.5% 4.8% 5.6% 5.2%
Entrepreneur
10-05-2025
- Business
- Entrepreneur
Wipro Appoints Sandeep Dhar as Global Head of GCC Practice
In his new role, Dhar will be responsible for leading Wipro's consulting-led and technology-enabled GCC strategy. He will report directly to Sanjeev Jain, Wipro's chief operating officer You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Wipro Limited has appointed Sandeep Dhar as the global head of its global capability center (GCC) practice, the company announced today. With over three decades of experience in the GCC ecosystem and consulting, Dhar is set to lead Wipro's efforts in transforming GCCs into AI-powered innovation and transformation hubs for global enterprises. In his new role, Dhar will be responsible for leading Wipro's consulting-led and technology-enabled GCC strategy. He will report directly to Sanjeev Jain, Wipro's chief operating officer. According to Wipro, the aim is to support global organizations in establishing and scaling future-ready capability centers that deliver both operational excellence and strategic value. "Wipro has been a trusted partner to GCCs for over two decades," said Sanjeev Jain, chief operating officer, Wipro Limited. "We are delighted to welcome Sandeep to our team. His vast experience in leading and transforming GCCs, combined with Wipro's robust capabilities and comprehensive suite of services for GCCs, will enable us to deliver superior business value to clients." Dhar has played a pivotal role in shaping some of the most recognized GCCs in the industry. As managing director, he was instrumental in transforming the Tesco and Goldman Sachs Consumer Bank GCCs into strategic engines of innovation and growth. Throughout his career, he has led profit and loss operations, driven digital transformation initiatives, and implemented cutting-edge engineering practices across diverse industries. Dhar, who assumes leadership of one of Wipro's key growth areas, emphasized the importance of aligning GCC operations with evolving enterprise goals. "As GCCs evolve to meet the dynamic business needs, enterprises require a trusted partner with the strategic vision to transform them into innovation hubs that drive impact," said Sandeep Dhar. "Wipro is ideally positioned to be the strategic partner of choice for GCCs, offering services that align with their objectives to establish, scale, transform or exit. I look forward to enhancing our focus and execution in this space."
&w=3840&q=100)
Business Standard
05-05-2025
- Health
- Business Standard
Akums secures patent for dual-action nausea drug for pregnant women
Akums Drugs & Pharmaceuticals has received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine, developed to manage nausea and vomiting in pregnancy (NVP). The formulation, using the company's proprietary 'tablet-in-tablet' technology, has been approved by the Drug Controller General of India (DCGI). NVP affects up to 80 per cent of pregnant women, with around 20 per cent experiencing symptoms throughout their pregnancy. The condition can impact nutrition, daily activity, and overall well-being. Akums' patented formulation combines immediate and sustained drug release in a single tablet, aimed at providing extended symptom relief and reducing dosing frequency. The outer layer of the tablet is designed for rapid onset, while the inner core provides a longer therapeutic effect. This dual-action mechanism is intended to improve dosing convenience and adherence. Commenting on the approval, Sanjeev Jain, Managing Director, Akums, said: 'This new formulation for managing nausea and vomiting during pregnancy ensures access to safe and effective care during a critical phase of life. With this, we are making life a little easier for expectant mothers and helping healthcare move closer to where it should be — accessible, reliable, and full of care.' The formulation has undergone a bioequivalence study. While subject numbers remain confidential as per regulatory norms, the data submitted was deemed sufficient for DCGI approval. Akums says the combination is positioned to address a treatment gap in pregnancy care by offering longer-lasting symptom control. Akums is a contract development and manufacturing organisation (CDMO) with 12 manufacturing units, four R&D centres, and more than 16,000 employees. It reports over 4,100 commercialised formulations and 220 products under development. The company's product pipeline spans multiple dosage forms and therapeutic categories. This development adds to Akums' existing portfolio of drug delivery innovations aimed at both domestic and export pharmaceutical markets.
The Hindu
25-04-2025
- Business
- The Hindu
Wipro announces GitHub Center of Excellence in Bengaluru to push AI advancement
Wipro has launched their GitHub Center of Excellence (COE) in Bengaluru. Under the IT major's ai360 initiative, CoE will serve as a hub for all GitHub-related innovation in Wipro. GitHub tools including GitHub Copilot and Microsoft M365 will be integrated into engineering teams in Wipro to push productivity and innovation at scale. The center will offer training initiatives including hackathons, workshops, codeathons and meetups to employees for upskilling. Additionally, the CoE will also create a Community of Practice to promote knowledge sharing and collaboration between teams via GitHub Champions and experts. These AI champions will be appointed at the CoE with training to ensure they're proficient at GitHub applications. The teams will also be taught how to deliver high-quality industry focused solutions efficiently. 'The launch of our GitHub CoE highlights our commitment to championing a culture of AI-first mindset with the right skillset and toolset amongst our workforce,' said Sanjeev Jain, Chief Operating Officer, Wipro Limited. 'We are equipping our developers with the best tools and practices and encouraging a culture of innovation to build future ready AI-powered industry and cross-industry solutions that solve our client's unique business challenges.' Kyle Daigle, Chief Operating Officer at GitHub, said, 'Wipro has long been a pioneer in innovation, and by rolling out GitHub Copilot at scale, they're showing the world what true transformation with AI looks like. The GitHub CoE is more than an investment–it's a blueprint for building with AI at the core. We're proud to build this future together–with the right tools, ingenuity, and a shared belief in what developers can achieve.'
